Tirzepatide Phase 4 Trial in Idiopathic Intracranial Hypertension Now Recruiting

A Phase 4 clinical trial evaluating tirzepatide in idiopathic intracranial hypertension is now listed as recruiting, according to a ClinicalTrials.gov update dated August 28, 2026. The study, registered as NCT07191873, is titled "Tirzepatide in Idiopathic Intracranial Hypertension Trial." Tirzepatide is an approved compound, and this trial represents further investigation in a specific patient population. The listing designates the trial as Phase 4, indicating it is being conducted after regulatory approval of the compound for its existing indications. Recruitment status means the trial is currently open and enrolling participants who meet study criteria. No outcomes, efficacy data, or safety findings have been reported as part of this update. The trial record does not specify enrollment numbers, estimated completion dates, or detailed endpoints beyond its title and current status. Readers should note that recruiting status only confirms that the study is underway and accepting participants, not that any results are available. Further updates to this trial's status, including any posted results, would be reflected in future ClinicalTrials.gov entries. For more background on this compound, readers can consult the tirzepatide overview.